Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Harnessing advanced data analysis for early detection, prevention and better outcomes
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
Subscribe To Our Newsletter & Stay Updated
